Article
Hematology
Jennifer R. Chapman, Alyssa C. Bouska, Weiwei Zhang, Juan Pablo Alderuccio, Izidore S. Lossos, Lisa M. Rimsza, Alanna Maguire, Shuhua Yi, Wing C. Chan, Francisco Vega, Joo Y. Song
Summary: In the era of cART, approximately half of HIV-DLBCL are EBV-related. HIV-DLBCL are enriched for MYC rearrangements and mutations, and lack BCL2 rearrangements regardless of EBV status. EBV-negative and EBV-positive HIV-DLBCL show important genetic and clinical differences, with the former having more mutations and higher mutation frequency for genes like TP53, SGK1, and EP300, while the latter occur in lower CD4 count, non-GCB origin, and recurrent STAT3 mutations.
BRITISH JOURNAL OF HAEMATOLOGY
(2021)
Review
Oncology
Sergio Pina-Oviedo, Carlos Ortiz-Hidalgo, Adrian Alejandro Carballo-Zarate, Alejandra Zarate-Osorno
Summary: Anaplastic large cell lymphoma (ALCL) is a subtype of CD30+ large T-cell lymphoma. It is divided into ALK+ and ALK- based on the expression of anaplastic lymphoma kinase (ALK), with different clinical and prognostic outcomes. Recent studies have identified recurrent genetic alterations in ALK- ALCL, some of which have prognostic value and may lead to potential targeted therapies for this subtype of TCL.
Article
Multidisciplinary Sciences
John W. Mellors, Shuang Guo, Asma Naqvi, Leah D. Brandt, Ling Su, Zhonghe Sun, Kevin W. Joseph, Dimiter Demirov, Elias K. Halvas, Donna Butcher, Beth Scott, Aaron Hamilton, Marintha Heil, Baktiar Karim, Xiaolin Wu, Stephen H. Hughes
Summary: HIV-1 infection increases cancer risk, mainly due to immunodeficiency and coinfection with oncogenic viruses. Proviruses integrated in genes like STAT3 and LCK can play a role in T cell lymphoma development. The development of these cancers involves additional nonviral mutations in a multistep process.
Article
Biochemistry & Molecular Biology
Carmen Caiazza, Teresa Brusco, Federica D'Alessio, Massimo D'Agostino, Angelica Avagliano, Alessandro Arcucci, Concetta Ambrosino, Giuseppe Fiume, Massimo Mallardo
Summary: This study demonstrates the important role of STING in antigen presentation. The absence of STING leads to impairment of peptide presentation and dampened immune response activation. This has significant implications for understanding the role of STING in immune mechanisms.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Pathology
Amr Fadl, Naoki Oishi, Min Shi, Surendra Dasari, Stephen M. Ansell, Rhett P. Ketterling, Andrew L. Feldman
Summary: Anaplastic large cell lymphoma (ALCL) is a heterogeneous disease with distinct clinical and genetic features. One genetic subgroup, characterized by DUSP22 rearrangements, shows equivocal findings in routine testing. This study aimed to further characterize these cases and found that they are clinically and pathologically heterogeneous, likely due to different types of DUSP22 rearrangements. The authors recommend reporting these cases as equivocal, separate from other genetic subgroups.
Article
Biochemistry & Molecular Biology
Jian Jin, Yiyi Shan, Liangliang Zhang, Zhengchang Wu, Shenglong Wu, Mingan Sun, Wenbin Bao
Summary: This study investigated the cytotoxicity induced by FB1 and explored the potential alleviating effect of PTE. The findings showed that FB1 induced cytotoxicity, apoptosis, pro-inflammatory cytokine production, and mitochondrial damage, which could be largely recovered by PTE treatment. Mechanistically, FB1 activated the JAK/STAT signaling pathway, while PTE attenuated FB1-induced cytotoxicity by inhibiting key JAK/STAT genes.
Article
Oncology
Y. Song, D. H. Yoon, H. Yang, J. Cao, D. Ji, Y. Koh, H. Jing, H. Eom, J. Kwak, W. Lee, J. Lee, H. Shin, J. Jin, M. Wang, Z. Yang, W. S. Kim, J. Zhu
Summary: Golidocitinib, an oral selective JAK1 inhibitor, demonstrates promising antitumor activity in patients with r/r PTCLs. It shows acceptable safety profile and tolerability in this phase I study, supporting its further investigation as a potential treatment option for r/r PTCLs.
ANNALS OF ONCOLOGY
(2023)
Article
Pharmacology & Pharmacy
Nicole M. Valenzuela
Summary: Chronic vascular inflammation is the basis of many diseases, and resolving inflammation is crucial for restoring homeostasis. Research shows that chronic activation is JAK1/2-dependent and characterized by adaptive chemokines.
VASCULAR PHARMACOLOGY
(2022)
Article
Chemistry, Medicinal
Dinoop Ravindran Menon, Yang Li, Takeshi Yamauchi, Douglas Grant Osborne, Prasanna Kumar Vaddi, Michael F. Wempe, Zili Zhai, Mayumi Fujita
Summary: This study demonstrates that EGCG enhances anti-tumor immune responses by inhibiting JAK-STAT signaling in melanoma. It could be used as an alternative treatment strategy to target the PD-L1/PD-L2-PD-1 axis in cancers.
Review
Oncology
Pier Paolo Piccaluga, Chiara Cascianelli, Giorgio Inghirami
Summary: Nodal peripheral T-cell lymphomas (PTCL) have a poor prognosis and lack reliable targets for therapy. Recent studies suggest tyrosine kinase (TK) deregulation may play a role in the development and treatment of PTCL, with ALK being a key example. Other TKs, such as PDGRFA and SYK, are also consistently expressed in PTCL. STAT proteins have been identified as downstream factors for most TKs involved.
FRONTIERS IN ONCOLOGY
(2023)
Article
Pathology
Akio Osakada, Masakazu Fujimoto, Chiyuki Ueshima, Yo Kaku, Momoko Nishikori, Norihito Inoue, Kengo Takeuchi, Hironori Haga
Summary: DUSP22-rearranged primary cutaneous anaplastic large-cell lymphoma (pcALCL) has a biphasic histological pattern, but the positivity rate of the biphasic pattern in DUSP22-rearranged pcALCL is unknown. LEF1 expression in >75% of tumor cells is associated with DUSP22-rearrangement in systemic ALCL, but whether this association applies to pcALCL remains unclear.
PATHOLOGY INTERNATIONAL
(2023)
Article
Pathology
Snjezana Dotlic, Maurilio Ponzoni, Rebecca L. King, Ilske Oschlies, Judith Ferry, Maria Calaminici, Santiago Montes-Moreno, John R. Goodlad, German Ott, Alexandra Traverse-Glehen
Article
Pathology
Julia Garcia-Reyero, Nerea Martinez Magunacelaya, Sonia Gonzalez de Villambrosia, Angela Gomez Mediavilla, Marcela Urquieta Lam, Andres Insunza, Raul Tonda, Sergi Beltran, Marta Gut, Ainara Gonzalez, Santiago Montes-Moreno
JOURNAL OF CLINICAL PATHOLOGY
(2020)
Article
Hematology
Julia Garcia-Reyero, Nerea Martinez Magunacelaya, Sonia Gonzalez de Villambrosia, Sanam Loghavi, Angela Gomez Mediavilla, Raul Tonda, Sergi Beltran, Marta Gut, Ainara Perena Gonzalez, Emmanuel D'Amore, Carlo Visco, Joseph D. Khoury, Santiago Montes-Moreno
Summary: The mutational profile of plasmablastic lymphoma is heterogeneous and related to EBV infection. Genetic events in MYC, STAT3, and PRDM1/Blimp1 are more frequent in EBV-positive disease. An enrichment in TAM and PD1 reactive T lymphocytes is found in the microenvironment of plasmablastic lymphoma, with a fraction of neoplastic cells expressing PD-L1.
Article
Oncology
Hui Zhou, Zijun Y. Xu-Monette, Ling Xiao, Paolo Strati, Fredrick Hagemeister, Yizi He, Huan Chen, Yajun Li, Ganiraju C. Manyam, Yong Li, Santiago Montes-Moreno, Miguel A. Piris, Ken H. Young
BLOOD CANCER JOURNAL
(2020)
Article
Biochemistry & Molecular Biology
Thaidy Moreno, Beatriz Monterde, Laura Gonzalez-Silva, Isabel Betancor-Fernandez, Carlos Revilla, Antonio Agraz-Doblas, Javier Freire, Pablo Isidro, Laura Quevedo, Rosa Blanco, Santiago Montes-Moreno, Laura Cereceda, Aurora Astudillo, Berta Casar, Piero Crespo, Cristina Morales Torres, Paola Scaffidi, Javier Gomez-Roman, Eduardo Salido, Ignacio Varela
Summary: This study found that 20% of lung cancer patients exhibit ARID2 protein loss, which leads to chromatin structural changes, enhanced cell proliferation and metastasis, and impaired DNA repair, increasing sensitivity to DNA-damaging agents. These findings suggest that ARID2 is a potential tumor suppressor gene and therapeutic target in lung cancer.
Review
Oncology
Nuria Garcia-Diaz, Miguel angel Piris, Pablo Luis Ortiz-Romero, Jose Pedro Vaque
Summary: In recent years, significant advancements have been made in the field of cutaneous T-cell lymphomas, particularly focusing on mycosis fungoides and Sezary syndrome. Next-generation sequencing data have greatly enhanced the understanding of molecular mechanisms underlying these diseases, leading to the development of new diagnostic tools and therapies. This review highlights the pathophysiology of MF/SS, the diagnostic and staging methods currently used, and the potential for targeted therapies based on key molecular mechanisms.
Article
Oncology
Sonia Gonzalez de Villambrosia, Mariana Bastos, Javier Menarguez Palanca, Jorge Gayoso Cruz, Jose-Tomas Navarro, Gustavo Tapia, Sara Alvarez Alonso, Alejandro Martin, Oscar Blanco, Pau Abrisqueta, Josep Castellvi, Ana Garcia-Noblejas, Reyes Arranz, Magdalena Adrados, Andres Lopez, Santiago Montes-Moreno
Summary: High Grade B Cell Lymphoma, NOS and High Grade B Cell Lymphoma with Dual Hit or Triple Hit were recently reclassified in the 2016 WHO classification. This study found that HGBCL NOS had better response to first line treatment compared to HGBCL with DH/TH, and only the presence of BCL2 translocation significantly affected PFS. Other clinical features were similar between the two categories, and both high grade and DLBCL morphological patterns showed equivalent PFS and OS.
LEUKEMIA & LYMPHOMA
(2022)
Article
Dermatology
Nuria Garcia-Diaz, Berta Casar, Ruth Alonso-Alonso, Laura Quevedo, Marta Rodriguez, Fulgencio Ruso-Julve, Anna Esteve-Codina, Marta Gut, Alejandro A. Gru, Maria Carmen Gonzalez-Vela, Ivo Gut, Jose Luis Rodriguez-Peralto, Ignacio Varela, Pablo Luis Ortiz-Romero, Miguel A. Piris, Jose Pedro Vaque
Summary: Research has shown that PKC theta plays a central role in activating malignant cutaneous T-cell lymphoma mechanisms through multiple routes. These mechanisms may serve as targets for specific therapies.
JOURNAL OF INVESTIGATIVE DERMATOLOGY
(2022)
Letter
Hematology
Edwin Uriel Suarez M, Alberto Lazaro-Garcia, Carlos Soto, Miguel Angel Piris
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY
(2022)
Article
Oncology
Giovanna Roncador, Joan Punet-Ortiz, Lorena Maestre, Luis Gerardo Rodriguez-Lobato, Scherezade Jimenez, Ana Isabel Reyes-Garcia, Alvaro Garcia-Gonzalez, Juan F. Garcia, Miguel Angel Piris, Santiago Montes-Moreno, Manuel Rodriguez-Justo, Mari-Pau Mena, Carlos Fernandez de Larrea, Pablo Engel
Summary: CD229 is a cell-surface molecule predominantly expressed on lymphocytes. This study investigated the expression of CD229 on various malignancies and normal tissues, showing that it is restricted to hematopoietic cells. The researchers also discovered that the presence of soluble CD229 in the sera of multiple myeloma patients could serve as a prognostic biomarker. These findings suggest that CD229 may be both a useful disease biomarker and a potential therapeutic target.
Review
Oncology
Rita Alaggio, Catalina Amador, Ioannis Anagnostopoulos, Ayoma D. Attygalle, Iguaracyra Barreto de Oliveira Araujo, Emilio Berti, Govind Bhagat, Anita Maria Borges, Daniel Boyer, Mariarita Calaminici, Amy Chadburn, John K. C. Chan, Wah Cheuk, Wee-Joo Chng, John K. Choi, Shih-Sung Chuang, Sarah E. Coupland, Magdalena Czader, Sandeep S. Dave, Daphne de Jong, Ming-Qing Du, Kojo S. Elenitoba-Johnson, Judith Ferry, Julia Geyer, Dita Gratzinger, Joan Guitart, Sumeet Gujral, Marian Harris, Christine J. Harrison, Sylvia Hartmann, Andreas Hochhaus, Patty M. Jansen, Kennosuke Karube, Werner Kempf, Joseph Khoury, Hiroshi Kimura, Wolfram Klapper, Alexandra E. Kovach, Shaji Kumar, Alexander J. Lazar, Stefano Lazzi, Lorenzo Leoncini, Nelson Leung, Vasiliki Leventaki, Xiao-Qiu Li, Megan S. Lim, Wei-Ping Liu, Abner Louissaint, Andrea Marcogliese, L. Jeffrey Medeiros, Michael Michal, Roberto N. Miranda, Christina Mitteldorf, Santiago Montes-Moreno, William Morice, Valentina Nardi, Kikkeri N. Naresh, Yasodha Natkunam, Siok-Bian Ng, Ilske Oschlies, German Ott, Marie Parrens, Melissa Pulitzer, S. Vincent Rajkumar, Andrew C. Rawstron, Karen Rech, Andreas Rosenwald, Jonathan Said, Clementine Sarkozy, Shahin Sayed, Caner Saygin, Anna Schuh, William Sewell, Reiner Siebert, Aliyah R. Sohani, Reuben Tooze, Alexandra Traverse-Glehen, Francisco Vega, Beatrice Vergier, Ashutosh D. Wechalekar, Brent Wood, Luc Xerri, Wenbin Xiao
Summary: This article provides an overview of the upcoming 5th edition of the World Health Organization classification of lymphoid tumors, highlighting changes from the previous edition such as reorganization of entities, modification of nomenclature, revision of diagnostic criteria, deletion of entities, introduction of new entities, and inclusion of tumor-like lesions.
Article
Pathology
Laura Rodriguez Merino, Aitana Avendano Pomares, Jose Revert Arce, Santiago Montes-Moreno
Summary: The aim of this study was to apply international consensus diagnostic criteria to classify 42 cases of Castleman disease (CD), and identify differences among unicentric CD, idiopathic multicentric Castleman disease (iMCD), HHV-8+ multicentric CD (HHV-8+MCD), and POEMS/plasma cell neoplasia (PCN)-associated CD. The results demonstrated that FDC proliferation was prominent in unicentric CD, while hypervascularity was increased in HHV-8+MCD, and germinal center hyperplasia was found only in iMCD cases and systemic lupus erythematosus (SLE). Monotypic plasma cells were readily identifiable in lymph node biopsies of PCN/POEMS-associated CD.
JOURNAL OF CLINICAL PATHOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Juan Carlos Caballero, Elham Askari, Nerea Carrasco, Miguel Angel Piris, Begona Perez de Camino, Laura Pardo, Javier Cornago, Jose Luis Lopez-Lorenzo, Pilar Llamas, Laura Solan
Summary: This article reports a case of a 77-year-old woman diagnosed with Waldenstrom macroglobulinemia (WM) following severe and sudden pancytopenia associated with cold agglutinin syndrome. Treatment with rituximab, corticosteroids, and cyclophosphamide was initiated to manage WM and underlying hemolysis. Despite improvements in hemolysis parameters, pancytopenia persisted and ibrutinib was started as a second-line treatment. The patient developed an uncommon invasive fungal infection (IFI) with bone marrow granulomatosis and myelofibrosis during treatment, highlighting a poor hematopoietic response and numerous complications.
Article
Medicine, General & Internal
Juan Carlos Caballero, Laura Pardo, Maria Socorro Rodriguez-Pinilla, Miguel Angel Piris, Beatriz Alvarez, Laura Solan, Javier Cornago, Jose Luis Lopez-Lorenzo, Pilar Llamas, Raul Cordoba, Alberto Lopez-Garcia
Summary: This article presents a rare case of a 25-year-old patient diagnosed with human immunodeficiency virus (HIV) and the development of primary effusion lymphoma (PEL), Kaposi's sarcoma (KS), and multicentric Castleman's disease (MCD). Despite intensive treatment, the patient's condition did not improve. This case highlights the need for new therapies and research in this field.
MEDICINA-LITHUANIA
(2023)
